← Back to search

PHATHOM PHARMACEUTICALS, INC.

PHAT · NASDAQ

Medicinal and Botanical Manufacturing

Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Phathom has in-licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a novel potassium competitive acid blocker (P-CAB) in late-stage development for the treatment of acid-related disorders.

ESG Scores

Overall ESG
7.0
Environmental
5.6
Social
5.0
Governance
5.2

Gender Diversity

Female Directors0.25%
Female Executives0.6341463414634146%
CEO GenderFemale